Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pregabalin + tramadol is a combination of two pharmaceutical agents used primarily for the management of neuropathic pain. Pregabalin is a structural analogue of gamma-aminobutyric acid (GABA) that binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby modulating the release of excitatory neurotransmitters such as glutamate, substance P, norepinephrine, and calcitonin gene-related peptide[6]. Tramadol is an opioid analgesic that acts as a weak agonist at the mu-opioid receptor and also inhibits reuptake of serotonin and norepinephrine. The combination has been shown to have synergistic or super-additive effects on pain relief in some studies[3][8], making it potentially more effective than either drug alone for certain types of chronic or neuropathic pain. However, combining these drugs increases the risk for central nervous system depression—including respiratory depression—and other adverse effects such as impaired coordination or coma; thus caution is advised when co-administering them[1][2][5]. Pharmacokinetic studies indicate no significant drug-drug interaction between pregabalin and tramadol when used together[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pregabalin + tramadol.